Science and Research
Gene Therapy Study to Evaluate the Safety and Efficacy of GT005 in people with Geographic Atrophy Secondary to Age-Related Macular Degeneration
This Phase II clinical study is exploring the safety and efficacy of two doses of GT005 administered as a single subretinal injection in people with geographic atrophy secondary to age-related macular degeneration.
Overview
This Phase II clinical study is exploring the safety and efficacy of two doses of GT005 administered as a single subretinal injection in people with geographic atrophy secondary to age-related macular degeneration.
Participants are randomised into either a treated or no treatment/control group and will be followed up for 2 years.
- Principal Investigator
Dr Thomas Edwards
This Phase II clinical study is exploring the safety and efficacy of two doses of GT005 administered as a single subretinal injection in people with geographic atrophy secondary to age-related macular degeneration.
Participants are randomised into either a treated or no treatment/control group and will be followed up for 2 years.
- Principal Investigator